Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 76 publications
Comparative analysis of selective fungal culture media and incubation conditions for Aspergillus fumigatus in cystic fibrosis sputum.
Journal: Microbiology spectrum
Published: May 29, 2026
Long-term reductions in inflammation in people with cystic fibrosis treated with elexacaftor/tezacaftor/ivacaftor.
Journal: Annals of the American Thoracic Society
Published: July 28, 2025
Optimized Monothiol Thioredoxin Derivative (ORP100S) Protects In Vitro and In Vivo from Radiation and Chemotoxicity Without Promoting Tumor Proliferation.
Journal: Advanced science (Weinheim, Baden-Wurttemberg, Germany)
Published: March 10, 2025
Home sputum collection for Aspergillus fumigatus detection in adults with cystic fibrosis.
Journal: ERJ open research
Published: March 03, 2025
Fecal microbiota changes in people with cystic fibrosis after 6 months of elexacaftor/tezacaftor/ivacaftor: Findings from the promise study.
Journal: Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society
Published: February 09, 2025
Cholesterol and triglyceride concentrations following 12-18 months of clinically prescribed elexacaftor-tezacaftor-ivacaftor-PROMISE sub-study.
Journal: Journal of clinical & translational endocrinology
Published: January 10, 2025
"Time out for an hour, every day, my whole life": understanding treatment burden in cystic fibrosis in the era of Elexacaftor/Tezacaftor/Ivacaftor (ETI).
Journal: Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society
Published: December 20, 2024
Elexacaftor/tezacaftor/ivacaftor's effects on cystic fibrosis infections are maintained, but not increased, after 3.5 years of treatment.
Journal: The Journal of clinical investigation
Published: September 05, 2024
Elexacaftor/Tezacaftor/Ivacaftor Markedly Reduces Aspergillus fumigatus in Cystic Fibrosis.
Journal: American journal of respiratory and critical care medicine
Published: August 27, 2024
Impact of Discontinuing Both Hypertonic Saline and Dornase Alfa after Elexacaftor-Tezacaftor-Ivacaftor in Cystic Fibrosis.
Journal: Annals of the American Thoracic Society
Published: July 23, 2024
Qualitative understanding of experiences of people with cystic fibrosis in a treatment discontinuation trial: The QUEST study.
Journal: Contemporary clinical trials
Published: July 22, 2024
What does it mean to be "healthy" when taking elexacaftor/tezacaftor/ivacaftor (ETI)? A qualitative study.
Journal: Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society
Published: June 24, 2024
Last Updated: 09/26/2026